Corin's Icona Femoral Stem Receives FDA Clearance for Direct Anterior Total Hip Arthroplasty

Key Insights

• Corin has obtained FDA 510(k) clearance for its Icona femoral stem, designed for direct anterior total hip arthroplasty, facilitating use in ambulatory surgery centers.
• The Icona femoral stem is a collared, metaphyseal-filling, triple-taper design, developed using data from the CorinRegistry for enhanced performance.
• Icona's design caters specifically to the direct anterior approach, featuring streamlined instrumentation to optimize efficiency in ambulatory surgery centers.

Corin has announced that it has received FDA 510(k) clearance for its Icona femoral stem, a device intended for use in direct anterior total hip arthroplasty (THA). The design of the Icona stem incorporates considerations for use in ambulatory surgery centers (ASCs).

The Icona femoral stem is distinguished by its collared, metaphyseal-filling, triple-taper design. According to Corin, the stem was developed using data from the CorinRegistry. This design is intended to optimize the biomechanical performance and stability of the implant in THA procedures.

Cynthia Ansari, chief commercial officer at Corin USA, stated that Icona reflects the implementation of real-world data in innovation, with design features tailored to the direct anterior approach and streamlined instrumentation for ASCs. The direct anterior approach is a surgical technique that may offer benefits such as reduced muscle damage and faster recovery times compared to traditional approaches.

The Icona femoral stem is currently available through a limited market release in the United States. This controlled release allows for careful monitoring of the device's performance and patient outcomes in a real-world clinical setting.